Neoadjuvant treatment of HER-2 positive breast cancer with trastuzumab plus pertuzumab combined with different chemotherapy regimens in real-world clinical practice: clinical efficacy and safety evaluation
-
摘要:
目的 比较曲妥珠单抗和帕妥珠单抗(trastuzumab plus pertuzumab,HP)联合紫杉类+铂类(TCbHP)、紫杉类单药(THP)、蒽环类序贯紫杉类(AC-THP)三种化疗方案在真实世界临床实践中新辅助治疗HER-2阳性乳腺癌的疗效、安全性及耐受性。 方法 回顾性分析2019年6月至2021年12月于保定市第一中心医院等河北省共11家三级甲等医院接受三种方案新辅助治疗并完成后续手术的180例HER-2阳性乳腺癌患者的临床病理资料,其中TCbHP组78例、THP组70例、AC-THP组32例,比较三种治疗方案的疗效、安全性及耐受性,并采用统计学方法分析临床病理因素对总体病理完全缓解(total pathologic complete response,tpCR)率的影响。 结果 总人群tpCR率为58.9%(106/180)。TCbHP组的tpCR率为64.1%(50/78),高于THP组的54.3%(38/70)和AC-THP组的56.3%(18/32),差异无统计学意义(P=0.454)。TCbHP组的3级及以上不良反应发生率为12.8%(10/78),高于THP组的4.3%(3/70)和AC-THP组的9.4%(3/32),差异无统计学意义(P=0.255)。THP组的既定方案完成率为98.6%(69/70),高于TCbHP组的92.3%(72/78)和AC-THP组的90.6%(29/32),差异无统计学意义(P=0.147)。180例患者中绝经后组与绝经前组的tpCR率分别为65.4%(70/107)与49.3%(36/73),HER-2免疫组织化学法(IHC)3+组与HER-2 IHC2+且荧光原位杂交(FISH)+组的tpCR率分别为65.0%(102/157)与17.4%(4/23),激素受体(HR)阴性组与HR阳性组的tpCR率分别为78.0%(64/82)与42.9%(42/98),白蛋白结合型紫杉醇组与其他紫杉类药物组的tpCR率分别为66.3%(65/98)与50.0%(41/82),组间进行比较差异均具有统计学意义(均P<0.05)。Logistic回归多因素分析表明,HER-2 IHC3+、HR阴性、使用白蛋白结合型紫杉醇为tpCR率的独立影响因素。 结论 TCbHP、THP、AC-THP方案新辅助治疗HER-2阳性乳腺癌在真实世界临床实践中疗效确切,安全性及耐受性良好。TCbHP方案可考虑作为HER-2阳性乳腺癌新辅助治疗的优选方案。 Abstract:Objective : To evaluate the efficacy, safety, and tolerability of trastuzumab plus pertuzumab (HP) combined with taxane + platinum (TCbHP), taxane (THP), and anthracycline sequential taxane (AC-THP) in the neoadjuvant therapy of HER-2 positive breast cancer in real-world clinical practice. Methods A retrospective investigation was conducted on the clinicopathological data of 180 patients with HER-2 positive breast cancer who received one of the three regimens of neoadjuvant therapy and underwent the follow-up surgeries between June 2019 and December 2021 at 11 3A-grade hospitals, including Baoding NO.1 Central Hospital. Among the patients, 78, 70, and 32 were assigned to the TCbHP, THP, and AC-THP groups, respectively. The effectiveness, safety, and tolerability of the three regimens were compared in addition to examining the influence of clinicopathological factors on the total pathologic complete response (tpCR) rate. Results The overall tpCR rate was 58.9% (106/180). The TCbHP group’s tpCR rate was 64.1% (50/78), which was higher than THP group’s 54.3% (38/70) and AC-THP group’s 56.3% (18/32), with no significant difference (P= 0.454). The incidence of ≥ grade 3 adverse reactions in the TCbHP group was 12.8% (10/78), which was higher than THP group’s 4.3% (3/70) and AC-THP group’s 9.4% (3/32), with no significant difference (P= 0.255). The THP group completed the given approaches at a rate of 98.6% (69/70), which was higher than TCbHP group’s 92.3% (72/78) and AC-THP group’s 90.6% (29/32), with no significant difference (P= 0.147). The tpCR rates of the 180 patients were 65.4% (70/107) and 49.3% (36/73) in the postmenopausal and premenopausal groups, respectively. In the HER-2 immunohistochemistry (IHC) 3+ group and HER-2 IHC2+ fluorescence in situ hybridization+ group, the tpCR rates were 65.0% (102/157) and 17.4% (4/23), respectively. The hormone receptor (HR)-negative and -positive groups had tpCR rates of 78.0% (64/82) and 42.9% (42/98), respectively. The tpCR rates were 66.3% (65/98) and 50.0% (41/82) in the albumin-bound paclitaxel group and other paclitaxel drug group, respectively. The differences between groups were significant (all P<0.05). Multivariate Logistic regression multivariate analysis revealed that HER-2 IHC3+, HR negative, and administered albumin-bound paclitaxel were independent factors affecting the tpCR rate. Conclusions Neoadjuvant TCbHP, THP, and AC-THP therapy for HER-2-positive breast cancer is effective, safe, and well tolerated in real-world clinical practice. The TCbHP regimen can be considered the preferred neoadjuvant treatment for HER-2-positive breast cancer. -
Key words:
- neoadjuvant therapy /
- HER-2 positive /
- breast cancer
-
表 1 HER-2阳性乳腺癌患者的临床病理资料
基本资料 总例数 TCbHP组 THP组 AC-THP组 (n=180) (n=78) (n=70) (n=32) 月经状态 绝经前 73(40.6) 29(37.2) 24(34.3) 20(62.5) 绝经后 107(59.4) 49(62.8) 46(65.7) 12(37.5) 合并症 无 114(63.3) 58(74.4) 33(47.1) 23(71.9) 有 66(36.7) 20(25.6) 37(52.9) 9(28.1) 肿瘤家族史 无 163(90.6) 71(91.0) 61(87.1) 31(96.9) 有 17(9.4) 7(9.0) 9(12.9) 1(3.1) cT(期) T1 7(3.9) 4(5.1) 2(2.9) 1(3.1) T2 114(63.4) 46(59.0) 46(65.7) 22(68.7) T3 26(14.4) 11(14.1) 9(12.8) 6(18.8) T4 33(18.3) 17(21.8) 13(18.6) 3(9.4) cN(期) N0 31(17.2) 12(15.4) 14(20.0) 5(15.6) N1 67(37.2) 29(37.2) 26(37.1) 12(37.5) N2 54(30.0) 23(29.5) 20(28.6) 11(34.4) N3 28(15.6) 14(17.9) 10(14.3) 4(12.5) cTNM(期) Ⅰ 2(1.1) 0(0) 2(2.9) 0(0) Ⅱ 74(41.1) 29(37.2) 32(45.7) 13(40.6) Ⅲ 104(57.8) 49(62.8) 36(51.4) 19(59.4) 组织学分级(级) G1 1(0.5) 0(0) 0(0) 1(3.1) G2 57(31.7) 22(28.2) 26(37.1) 9(28.1) G3 7(3.9) 3(3.9) 3(4.3) 1(3.1) 不详 115(63.9) 53(67.9) 41(58.6) 21(65.7) HR 阴性 82(45.6) 33(42.3) 35(50.0) 14(43.8) 阳性 98(54.4) 45(57.7) 35(50.0) 18(56.2) HER-2 IHC 3+ 157(87.2) 70(89.7) 64(91.4) 23(71.9) IHC 2+且FISH+ 23(12.8) 8(10.3) 6(8.6) 9(28.1) Ki67(%) ≤30 80(44.4) 35(44.9) 30(42.9) 15(46.9) >30 100(55.6) 43(55.1) 40(57.1) 17(53.1) 紫杉药物种类 白蛋白结合型紫杉醇 98(54.4) 47(60.3) 33(47.1) 18(56.2) 其他紫杉类药物 82(45.6) 31(39.7) 37(52.9) 14(43.8) 新辅助治疗周期数(个) 4 20(11.1) 3(3.8) 17(24.2) 0(0) 5 3(1.7) 1(1.3) 0(0) 2(6.3) 6 121(67.2) 72(92.3) 49(70.0) 0(0) 7 2(1.1) 0(0) 2(2.9) 0(0) 8 33(18.3) 2(2.6) 2(2.9) 29(90.6) 10 1(0.6) 0(0) 0(0) 1(3.1) 术式 改良根治术 167(92.8) 72(92.3) 65(92.8) 30(93.8) 乳房全切+前哨 5(2.8) 1(1.3) 2(2.9) 2(6.2) 保乳根治术 5(2.8) 4(5.1) 1(1.4) 0(0) 根治术 3(1.6) 1(1.3) 2(2.9) 0(0) 辅助全身治疗 HP 111(61.6) 53(67.9) 41(58.6) 17(53.2) T-DM1 2(1.1) 1(1.3) 1(1.4) 0(0) HP+化疗 12(6.7) 2(2.6) 9(12.9) 1(3.1) HP+内分泌治疗 50(27.8) 21(26.9) 16(22.8) 13(40.6) 其他 5(2.8) 1(1.3) 3(4.3) 1(3.1) 辅助放疗 是 123(68.3) 65(83.3) 35(50.0) 23(71.9) 否 57(31.7) 13(16.7) 35(50.0) 9(28.1) ()内单位为%;HR:激素受体;IHC:免疫组织化学;FISH:荧光原位杂交;T-DM1:恩美曲妥珠单抗 表 2 三种治疗方案疗效、安全性、耐受性的比较
研究终点 TCbHP组(n=78) THP组(n=70) AC-THP组(n=32) χ2 P 例数(例) 百分比(%) 例数(例) 百分比(%) 例数(例) 百分比(%) tpCR率 50 64.1 38 54.3 18 56.3 1.580 0.454 3级及以上不良反应发生率 10 12.8 3 4.3 3 9.4 2.733 0.255 既定方案完成率 72 92.3 69 98.6 29 90.6 3.841 0.147 表 3 临床病理因素对总人群和三种治疗方案tpCR率的影响
临床病理因素 180例总人群tpCR率(%) χ2 P 三种治疗方案tpCR率(%) χ2 P TCbHP组(n=78) THP组
(n=70)AC-THP组
(n=32)月经状态 绝经前 49.3(36/73) 4.649 0.031 57.1(15/29) 41.7(10/24) 55.0(11/20) 0.888 0.642 绝经后 65.4(70/107) 71.4(35/49) 60.9(28/46) 58.3(7/12) 1.469 0.480 合并症 无 57.9(66/114) 0.127 0.722 63.8(37/58) 51.5(17/33) 52.2(12/23) 1.688 0.430 有 60.6(40/66) 65.0(13/20) 56.8(21/37) 66.7(6/9) 0.530 0.767 cT(期) T1~2 58.7(71/121) 0.007 0.934 62.0(31/50) 56.2(27/48) 56.5(13/23) 0.388 0.824 T3~4 59.3(35/59) 67.9(19/28) 50.0(11/22) 55.6(5/9) 1.690 0.429 cN(期) N0~1 59.2(58/98) 0.008 0.930 61.0(25/41) 62.5(25/40) 47.1(8/17) 1.271 0.530 N2~3 58.5(48/82) 67.6(25/37) 43.3(13/30) 66.7(10/15) 4.509 0.105 HR 阴性 78.0(64/82) 22.838 <0.001 81.8(27/33) 65.7(23/35) 100.0(14/14) 7.319 0.026 阳性 42.9(42/98) 51.1(23/45) 42.9(15/35) 22.2(4/18) 4.381 0.112 HER-2 IHC 3+ 65.0(102/157) 18.757 <0.001 68.6(48/70) 57.8(37/64) 73.9(17/23) 2.648 0.266 IHC 2+且FISH+ 17.4(4/23) 25.0(2/8) 16.7(1/6) 11.1(1/9) 0.571 0.752 Ki67(%) ≤30 62.5(50/80) 0.776 0.378 68.6(24/35) 63.3(19/30) 46.7(7/15) 2.164 0.339 >30 56.0(56/100) 60.5(26/43) 47.5(19/40) 64.7(11/17) 2.044 0.360 紫杉药物种类 白蛋白结合型紫杉醇 66.3(65/98) 4.915 0.027 72.3(34/47) 57.6(19/33) 66.7(12/18) 1.893 0.388 其他紫杉类药物 50.0(41/82) 51.6(16/31) 51.4(19/37) 42.9(6/14) 0.345 0.842 新辅助治疗周期数(个) <6 73.9(17/23) 2.459 0.117 75.0(3/4) 76.5(13/17) 50.0(1/2) 0.653 0.721 ≥6 56.7(89/157) 63.5(47/74) 47.2(25/53) 56.7(17/30) 3.360 0.186 表 4 影响总人群tpCR率的Logistic回归多因素分析
临床病理因素 OR 95%CI P 月经状态(绝经前 vs. 绝经后) 1.862 0.922~3.760 0.083 合并症(有 vs. 无) 0.903 0.439~1.855 0.781 cT(T1~2期 vs. T3~4期) 0.977 0.469~2.036 0.950 cN(N0~1期 vs. N2~3期) 0.897 0.447~1.799 0.759 HR(阴性 vs. 阳性) 0.264 0.127~0.548 <0.001 HER-2(IHC3+ vs. IHC2+且FISH+) 0.165 0.050~0.547 0.003 Ki67(≤30% vs.>30%) 1.018 0.499~2.077 0.962 紫杉类药物(白蛋白结合型紫杉醇vs.其他紫杉类药物) 2.648 1.284~5.462 0.008 新辅助治疗周期数(<6个 vs. ≥6个) 0.383 0.118~1.245 0.111 -
[1] Waks AG, Winer EP. Breast cancer treatment: a review[J]. JAMA, 2019, 321(3):288-300. doi: 10.1001/jama.2018.19323 [2] Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial[J]. Lancet Oncol, 2012, 13(1):25-32. doi: 10.1016/S1470-2045(11)70336-9 [3] Shao ZM, Pang D, Yang HJ, et al. Efficacy, safety, and tolerability of pertuzumab, trastuzumab, and docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia: the PEONY phase 3 randomized clinical trial[J]. JAMA Oncol, 2020, 6(3):e193692. doi: 10.1001/jamaoncol.2019.3692 [4] 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2021年版)[J].中国癌症杂志,2021,31(10):954-1040. doi: 10.19401/j.cnki.1007-3639.2021.10.013 [5] 《中国乳腺癌新辅助治疗专家共识(2022年版)》专家组.中国乳腺癌新辅助治疗专家共识(2022年版)[J].中国癌症杂志,2022,32(1):80-88. doi: 10.19401/j.cnki.1007-3639.2022.01.011 [6] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会乳腺癌诊疗指南(2022年版)[M]. 北京: 人民卫生出版社, 2022. [7] 马祥敏,张香梅,周新平,等.曲妥珠单抗和帕妥珠单抗联合化疗对HER2阳性乳腺癌新辅助治疗的真实世界研究[J].肿瘤防治研究,2022,49(1):46-52. [8] Xu B, Shen JG, Zhang LW, et al. HER2 protein expression level is positively associated with the efficacy of neoadjuvant systemic therapy in HER2-positive breast cancer[J]. Pathol Res Pract, 2022, 234:153900. doi: 10.1016/j.prp.2022.153900 [9] 刘建兰,陈黛诗,胡泓,等.HER2阳性浸润性乳腺癌新辅助治疗反应的预测因子及治疗前后HER2状态变化的评估[J].中国癌症杂志,2022,32(5):417-426. doi: 10.19401/j.cnki.1007-3639.2022.05.007 [10] Yin WJ, Wang YH, Wu ZP, et al. Neoadjuvant trastuzumab and pyrotinib for locally advanced HER2-positive breast cancer (NeoATP): primary analysis of a phase II study[J]. Clin Cancer Res, 2022, 28(17):3677-3685. doi: 10.1158/1078-0432.CCR-22-0446 [11] van Ramshorst MS, van der Voort A, van Werkhoven ED, et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2018, 19(12):1630-1640. doi: 10.1016/S1470-2045(18)30570-9 [12] Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)[J]. Ann Oncol, 2013, 24(9):2278-2284. doi: 10.1093/annonc/mdt182 [13] Untch M, Jackisch C, Schneeweiss A, et al. NAB-paclitaxel improves disease-free survival in early breast cancer: GBG 69-GeparSepto[J]. J Clin Oncol, 2019, 37(25):2226-2234. doi: 10.1200/JCO.18.01842 [14] Hurvitz SA, Martin M, Symmans WF, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial[J]. Lancet Oncol, 2018, 19(1):115-126. doi: 10.1016/S1470-2045(17)30716-7 [15] Hatschek T, Foukakis T, Bjöhle J, et al. Neoadjuvant trastuzumab, pertuzumab, and docetaxel vs trastuzumab emtansine in patients with ERBB2-positive breast cancer: a phase 2 randomized clinical trial[J]. JAMA Oncol, 2021, 7(9):1360-1367. doi: 10.1001/jamaoncol.2021.1932
计量
- 文章访问数: 189
- HTML全文浏览量: 46
- PDF下载量: 33
- 被引次数: 0